Prognostic value of soluble ST2 in an unselected cohort of patients admitted to an intensive care unit — The Linz Intensive Care Unit (LICU) study

Dieplinger, Benjamin; Egger, Margot; Köehler, Wolfgang; Firlinger, Fritz; Poelz, Werner; Lenz, Kurt; Haltmayer, Meinhard; Mueller, Thomas

doi:10.1016/j.cca.2011.11.028

Cited by 16 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We used the 256 consecutive baseline EDTA plasma samples of patients admitted to the medical intensive care unit of the Konventhospital Barmherzige Brueder Linz, Austria. This cohort of the LICU study was recruited from August 9th 2009 to February 8th 2010 [10].…”

Section: Derivation Cohort Of the Linz Intensive Care Unit (Licu) Studymentioning

confidence: 99%

Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma

Bundschuh

Egger

Wiesinger

et al. 2020

Clinica Chimica Acta

Self Cite

View full text Add to dashboard Cite

Section: Derivation Cohort Of the Linz Intensive Care Unit (Licu) Studymentioning

confidence: 99%

Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma

Bundschuh

Egger

Wiesinger

et al. 2020

Clinica Chimica Acta

Self Cite

View full text Add to dashboard Cite

“…In non‐AL amyloidosis populations, elevations of sST2 are predictive of mortality in patients with congestive heart failure , ST elevation acute coronary syndrome , non‐ST elevation acute coronary syndrome , and stable coronary artery disease . High sST2 has been shown to predict all‐cause mortality among patients admitted to ICU , patients presenting to emergency department with acute dyspnea , cardiac transplantation patients , and normal patient populations . In several of these settings, sST2 has been shown to be independent of NT‐proBNP and troponins .…”

Section: Discussionmentioning

confidence: 99%

Soluble suppression of tumorigenicity 2 (sST2), but not galactin‐3, adds to prognostication in patients with systemic AL amyloidosis independent of NT‐proBNP and troponin T

et al. 2015

View full text Add to dashboard Cite

The use of soluble cardiac biomarkers such as N-terminal pro-brain natriuretic peptide (NT-proBNP) and troponin has revolutionized prognostication for patients with AL amyloidosis. Soluble ST2 (sST2) and galectin-3 have also been reported to have prognostic value in other cardiac patient populations. We identified 502 patients with AL amyloidosis, who provided a research sample and consent to review their medical records between 1/1/2006-12/31/2010 within 90 days of their diagnosis. Samples were assayed for sST2 and galectin-3. Within this AL amyloidosis population, overall survival (OS) was 25.5 months (95% CI 18, 35.7 months). Receiver operating curve analyses were done to detect the best cut-points for sST2 and galectin-3 to predict both 1-and 5-year OS. The respective cut points for sST2 were 30 and 29.7 ng/mL, while the median sST2 for the entire population was 31 ng/mL (IQR 19.8, 53.6). The respective cut points for galectin-3 were 11 and 10.4 ng/mL while the median for the entire population was 16.6 ng/mL (IQR 11.5, 24.0). Although on univariate analysis, both sST2 and galectin-3 were prognostic, upon multivariate analysis, only sST2 was independent of troponin, NT-proBNP, serum immunoglobulin free light chain, and blood pressure. Not only did sST2 add to previously reported prognostication systems, but a novel prognostication 5-point system including sST2 was possible. The addition of sST2 -but not galectin-3 -to existing prognostication systems for patients with AL amyloidosis strengthens the ability to predict for death.

show abstract

Prognostic markers of acute decompensated heart failure: The emerging roles of cardiac biomarkers and prognostic scores

Cohen‐Solal

Laribi

Ishihara

et al. 2015

Archives of Cardiovascular Diseases

View full text Add to dashboard Cite

Rapidly assessing outcome in patients with acute decompensated heart failure is important but prognostic factors may differ from those used routinely for stable chronic heart failure. Multiple plasma biomarkers, besides the classic natriuretic peptides, have recently emerged as potential prognosticators. Furthermore, prognostic scores that combine clinical and biochemical data may also be useful. However, compared with the scores used in chronic heart failure, scores for acute decompensated heart failure have not been validated. This article reviews potential biomarkers, with a special focus on biochemical biomarkers, and possible prognostic scores that could be used by the clinician when assessing outcome in patients with acute heart failure.

show abstract

Prognostic value of soluble ST2 in an unselected cohort of patients admitted to an intensive care unit — The Linz Intensive Care Unit (LICU) study

Cited by 16 publications

References 35 publications

Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma

Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma

Soluble suppression of tumorigenicity 2 (sST2), but not galactin‐3, adds to prognostication in patients with systemic AL amyloidosis independent of NT‐proBNP and troponin T

Prognostic markers of acute decompensated heart failure: The emerging roles of cardiac biomarkers and prognostic scores

Contact Info

Product

Resources

About